Lacosamide Safety During Pregnancy and Breastfeeding: A Single-Centre Experience and Comprehensive Narrative Review
Open Access
Abstract
(1) Background: The management of epilepsy during pregnancy requires balancing effective seizure control against potential teratogenic effects of antiseizure medications (ASMs). Data on the safety of lacosamide (LCM), a third-generation ASM, during pregnancy and breastfeeding are limited. (2) Methods: To evaluate the safety and efficacy of LCM during pregnancy and breastfeeding, we report a single-centre case series and provide a comprehensive narrative review of the literature. (3) Results: In total, 22 cases of maternal exposure to LCM throughout pregnancy (1 monotherapy, 21 polytherapy) were identified, resulting in 21 live births (95.5%). Congenital malformations (atrial septal defect) were observed in one offspring exposed to LCM and levetiracetam (4.8%). Twelve newborns were breastfed (57.1%) without neurodevelopmental delay after twelve months. The literature search identified 16 studies, overall reporting data on 627 pregnancies with LCM (236 monotherapy, 391 polytherapy). Among 632 available pregnancy outcomes (3 twin pregnancies and 1 triplet in the polytherapy group) the proportion of live births was 81.3% (514/632). Major congenital malformations were reported in 2.5% (6/236) with LCM monotherapy and 11.9% (47/396) with polytherapy. (4) Conclusions: According to the literature, no major safety concerns, especially in LCM monotherapy, and no specific malformations associated with LCM exposure were identified. Conclusions are limited by the heterogeneity of studies and the small number of monotherapy-exposed cases. Larger, prospective studies with longer follow-up are required.Keywords
This publication has 38 references indexed in Scilit:
- Safety concerns of maternal antiseizure medications exposure on perinatal and offspring outcomes: a disproportionality analysis based on FDA adverse event reporting systemJournal of Neurology, 2025
- The use of newer anti-seizure medicines in women with epilepsy in pregnancy: A case seriesEpilepsy & Behavior Reports, 2025
- Risk of Major Congenital Malformations and Exposure to Antiseizure Medication MonotherapyJAMA Neurology, 2024
- Prenatal exposure to antiseizure medications and fetal growth: a population-based cohort study from the Nordic countriesThe Lancet Regional Health - Europe, 2024
- Neonatal Cardiac Arrest Following Lacosamide Treatment: A Case ReportPediatric Neurology, 2023
- Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual DisabilityJAMA Neurology, 2022
- Anti N-methyl-D-aspartate receptor (NMDAr) encephalitis during pregnancy: A case reportEpilepsy & Behavior Reports, 2022
- Lacosamide Levels in Blood and Breastmilk During Pregnancy and Lactation: A Case ReportReproductive Toxicology, 2020
- Lacosamide during pregnancy and breastfeedingNeurologia i Neurochirurgia Polska, 2017
- Early pregnancy cerebral venous thrombosis and status epilepticus treated with levetiracetam and lacosamide throughout pregnancyReproductive Toxicology, 2015